Zotizalkib

DB19238InvestigationalSmall molecule

Zotizalkib: Overview.

Mechanism: Pharmacologically active on ALK tyrosine kinase receptor
Curator reviewed
Formula / weight: C₂₁H₂₀F₃N₅O₃ · 447.418 g/mol (avg)
Also known as: 18,1-METHENO-6H-(1,4)OXAZINO(3,4-I)PYRAZOLO(4,3-F)(1,4,8,10)BENZOXATRIAZACYCLOTRIDECIN-15(12H)-ONE, 4-(DIFLUOROMETHYL)-8-FLUORO-3,4,13,14-TETRAHYDRO-13,13-DIMETHYL-, (4S)-
Code names: TPX-0131

Resolves to

Compound

Structure

InChIKeyILAMRXVQSGVCJX-AWEZNQCLSA-NSMILESCC1(C)COC2=CC=C(F)C=C2CN2[C@@H](COC3=CN4N=CC(=C4N=C23)C(=O)N1)C(F)F

Targets

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Zotizalkib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.